In preclinical patient-derived glioma models, 5-Aza treatment was reported to inhibit tumor proliferation and induce cell differentiation only in tumors that harbor mutations in isocitrate dehydrogenase 1 (IDH1-R132H) gene [21,22]. The gene discussed is IDH1; the disease is glioma.